<?xml version='1.0' encoding='utf-8'?>
<document id="23076661"><sentence text="Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug-drug interaction."><entity charOffset="0-12" id="DDI-PubMed.23076661.s1.e0" text="Atorvastatin" /></sentence><sentence text="A 75-year-old man developed rhabdomyolysis and acute renal failure during atorvastatin therapy"><entity charOffset="74-86" id="DDI-PubMed.23076661.s2.e0" text="atorvastatin" /></sentence><sentence text=" All medications were discontinued and the patient was treated with intermittent hemodialysis throughout the course of hospitalization" /><sentence text=" After four weeks, patient's kidney function tests and serum myoglobin levels decreased to normal values and muscle weakness gradually disappeared" /><sentence text=" Genotyping results showed that the patient had a single-nucleotide polymorphism within genes encoding the organic anion-transporting polypeptide 1B1 and ATP binding cassette sub-family B member 1, which predisposed him for statin-induced myopathy" /><sentence text=" He was also a poor metabolizer of cytochrome P450 2C19" /><sentence text=" Concomitant therapy with pantoprazole could have resulted in the inhibition of cytochrome P450 3A4-mediated metabolism of atorvastatin and contributed to the development of rhabdomyolysis"><entity charOffset="26-38" id="DDI-PubMed.23076661.s7.e0" text="pantoprazole" /><entity charOffset="123-135" id="DDI-PubMed.23076661.s7.e1" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.23076661.s7.e0" e2="DDI-PubMed.23076661.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23076661.s7.e0" e2="DDI-PubMed.23076661.s7.e1" /></sentence><sentence text="" /><sentence text="The case illustrates the clinical relevance and relationship between pharmacogenetic and pharmacokinetic factors in the development of statin-induced myopathy" /><sentence text="" /></document>